费城染色体样急性淋巴细胞白血病的临床诊断与治疗策略
费城染色体样B细胞急性淋巴细胞白血病(Ph-like ALL)占较大儿童、青少年和成人B-ALL的15%至30%,常规治疗失败和复发率高。当前临床试验正在评估在化疗基础上加用酪氨酸激酶抑制剂(TKI)对携带ABL类易位或CRLF2重排及其他JAK通路改变的Ph-like ALL患者的疗效。该病遗传异质性强且改变常隐匿于核型,实时诊断困难,本文综述其生物学与临床特征、诊断检测方法及治疗策略,并提出分步基因检测的实用方法。
要点
- Ph-like ALL占较大儿童、青少年和成人B-ALL的15%至30%,常规治疗失败和复发率高。
- 临床试验评估TKI联合化疗用于ABL类易位或CRLF2重排/JAK通路改变的Ph-like ALL。
- 推荐分步基因检测以识别患者并分配至TKI临床试验或可用药物治疗。
核心结论
- Ph-like ALL是高风险亚型,当前临床试验评估TKI联合化疗的疗效。
- 提出分步基因检测方法有助于将患者分配至TKI为基础的临床试验或商业药物。
研究设计与样本
- 综述,讨论Ph-like ALL跨年龄的生物学与临床特征、诊断检测方法及治疗策略。
主要发现
- Ph-like ALL占较大儿童、青少年和成人B-ALL的15%至30%,常规治疗失败和复发率高。
- 该病遗传异质性强,相关改变常隐匿于核型,实时诊断具有挑战性。
关键数值与推荐
- 临床试验评估在化疗基础上加用TKI用于携带ABL类易位或CRLF2重排及其他JAK通路改变的患者。
临床怎么用
- 采用分步基因检测方法识别Ph-like ALL患者,并分配至TKI为基础的临床试验或商业药物。
- 提高诊断效率与敏感性、缩短检测回报时间,可能促进更早治疗干预并改善预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of B-cell acute lymphoblastic leukemia in older children, adolescents, and adults and is associated with high rates of conventional treatment failure and relapse. Current clinical trials are assessing the efficacy of the addition of tyrosine kinase inhibitors (TKIs) to chemotherapy for children and adults with Ph-like ALL harboring ABL class translocations or CRLF2 rearrangements and other JAK pathway alterations. However, real-time diagnosis of patients can be quite challenging given the genetic heterogeneity of this disease and the often cytogenetically cryptic nature of Ph-like ALL-associated alterations. In this review, we discuss the complex biologic and clinical features of Ph-like ALL across the age spectrum, available diagnostic testing modalities, and current clinical treatment strategies for these high-risk patients. We further propose a practical and step-wise approach to Ph-like ALL genetic testing to facilitate the identification and allocation of patients to appropriate clinical trials of TKI-based therapies or commercially available drugs. Although the majority of patients with Ph-like ALL can be successfully identified via current clinical assays by the end of induction chemotherapy, increasing diagnostic efficiency and sensitivity and decreasing time to test resulting will facilitate earlier therapeutic intervention and may improve clinical outcomes for these high-risk patients.
引用
- Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Adv. 2020. PMID: 31935290. doi:10.1182/bloodadvances.2019000163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。